Committed Investment: December, 2020
Status : Active Portfolio Company
Retham Technologies (Milwaukee) is a diagnostics company developing an in vitro diagnostic assay for the diagnosis of Heparin-induced thrombocytopenia (HIT), a disease which kills five people per day in the United States. Retham developed a method of stabilizing platelets for at least one year, whereas platelets typically live only a few days.
